Scientiae Radices 5(2) 102-115 (2026)

Review

Human-in-the-Loop Artificial Intelligence in Pharmaceutical Industry: Enhancing Efficiency and Maintaining Oversight

Seyyed Amir Siadati[1]*, Mohammad Ali Ebrahimzadeh[2], and Akbar Dadras[3]

[1] Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
[2] Department of Medicinal Chemistry, The head Sari school of pharmacy, Sari, 4815733971, Iran
[3] R&D Department, Shimi-Daruee Pharmaceutical Company, TPICO, Tehran, Iran
* Correspondence to: Chemistry_2021@yahoo.com

Abstract

Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, offering unprecedented opportunities to accelerate drug discovery, optimize synthesis, and improve quality control. Despite its potential, unmonitored AI implementation carries significant risks, including errors in prediction, regulatory non-compliance, and ethical challenges. This perspective article explores the integration of AI across key stages of pharmaceutical research and development, including drug design, clinical trials, synthesis, analysis, and formulation, with an emphasis on human-in-the-loop supervision. We highlight areas where AI can deliver maximum efficiency gains and identify stages that require intensive human oversight to ensure safety, reliability, and regulatory adherence. By examining current applications and limitations, this article proposes a framework for combining AI capabilities with expert human judgment, aiming to enhance productivity while minimizing risk. Finally, we discuss future directions, including adaptive AI systems and hybrid models that promise to transform pharmaceutical operations without compromising ethical and scientific standards.

Keywords: artificial intelligence (AI), pharmaceutical industries, human supervision, drug synthesis



Received: 2026.02.18
Accepted: 2026.05.06
Published: 2026.06.17

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

1. Introduction

Artificial intelligence (AI) has emerged as one of the most transformative technological developments of the twenty-first century. By enabling machines to learn from data, recognize patterns, and make predictive decisions, AI has fundamentally altered how complex problems are approached across industries [1], [2]. From finance and logistics to healthcare and materials science, AI systems have demonstrated an unparalleled capacity to process vast datasets at speeds far beyond human capability. Machine learning, deep learning, and data-driven optimization techniques allow for continuous improvement of predictive accuracy, adaptive modeling, and automation of repetitive tasks [3]. Importantly, AI does not merely accelerate computation; it enhances decision-making by uncovering hidden correlations that may not be immediately evident to human analysts. As industries increasingly rely on high-dimensional data and multifactorial systems, AI provides tools capable of navigating such complexity efficiently. Toward the life sciences, and particularly pharmaceuticals, the relevance of AI becomes even more pronounced [4]. Drug discovery and development inherently involve massive datasets, nonlinear biological interactions, and multistep production processes. Consequently, the integration of AI into pharmaceutical research and industrial operations offers the promise of reducing development time, lowering costs, and improving precision, positioning AI as a potentially indispensable tool in modern drug development [5].

Within the pharmaceutical domain, AI has demonstrated substantial capabilities across multiple stages of research and development. In early drug discovery, machine learning algorithms can analyze chemical libraries, predict molecular activity, and identify promising compounds with remarkable efficiency [6]. Structure-based modeling, quantitative structure–activity relationship (QSAR) approaches, and generative models allow researchers to explore chemical space far beyond traditional experimental limits [7]-[9]. In parallel, AI-driven analysis of genomic and proteomic datasets supports target identification and biomarker discovery, accelerating the understanding of disease mechanisms. Beyond discovery, AI contributes to clinical trial design by optimizing patient stratification, predicting therapeutic responses, and assisting in adaptive protocol development. Data management systems powered by AI can monitor adverse events and detect patterns in real time, supporting evidence-based decisions [10]. In manufacturing environments, AI algorithms are capable of monitoring process variables, predicting deviations, and enhancing quality assurance. Despite these extensive capabilities, the application of AI in pharmaceuticals requires careful validation, regulatory compliance, and expert interpretation. Therefore, while AI significantly expands analytical and predictive capacity, its effective deployment depends on structured integration within existing scientific and industrial frameworks.

Traditionally, drug synthesis and analytical characterization have relied heavily on empirical experimentation, incremental optimization, and expert intuition [11]-[14]. Synthetic route development typically involves stepwise experimentation in which reaction conditions such as temperature [15], [16], solvent choice [17], [18], reagent ratios [19], [20], and catalysts [21], [22] are adjusted through iterative laboratory trials. Chemists depend on mechanistic understanding, prior literature [23]-[26], and accumulated experience to refine reaction pathways and minimize by-products. Scale-up from laboratory to industrial production introduces additional complexity, including heat transfer limitations, mixing efficiency, impurity profiles, and safety constraints [27], [28]. Similarly, analytical techniques such as high-performance liquid chromatography (HPLC) [29], [30], gas chromatography (GC) [31], [32], nuclear magnetic resonance (NMR) [33], [34], and mass spectrometry (MS) [35], [36] require meticulous method development and manual interpretation. Peak assignment, impurity identification, and validation procedures demand significant time and expert evaluation [37], [38]. Quality control processes are governed by strict regulatory standards, necessitating extensive documentation and repeated verification [39]-[41]. Although these conventional approaches have produced countless successful therapeutics, they are often time-consuming, resource-intensive, and susceptible to human error or variability. The increasing molecular complexity of modern drug candidates further amplifies these challenges. As pharmaceutical pipelines expand and timelines tighten, reliance solely on traditional empirical methodologies may limit efficiency and scalability in contemporary drug development environments [42], [43].

Before the rise of artificial intelligence, computational tools had already begun reshaping pharmaceutical research through molecular modeling and quantum chemical calculations [44]-[47]. Early applications of computational chemistry enabled researchers to approximate molecular geometries, predict reaction energetics, and explore mechanistic pathways using theoretical frameworks grounded in quantum mechanics [48]-[50]. Methods such as ab initio calculations and density functional theory (DFT) provided insights into transition states, activation barriers, and electronic distributions, offering a deeper

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

understanding of reaction mechanisms. These approaches marked the first significant integration of computer-based modeling into drug synthesis and mechanistic studies [51]-[54]. Although computationally demanding, such calculations allowed chemists to rationalize experimental outcomes and design more efficient synthetic routes. In medicinal chemistry, molecular docking and early simulation techniques provided preliminary estimates of ligand–target interactions, representing foundational steps toward data-driven drug design [55], [56]. However, these quantum and semi-empirical methods were limited by computational cost, scalability constraints, and simplified system representations. They typically required expert interpretation and could not easily accommodate the enormous chemical spaces involved in modern drug discovery. Nevertheless, these pioneering computational strategies laid the conceptual groundwork for today's data-intensive approaches, bridging traditional experimental chemistry and advanced algorithmic methodologies that now define AI-assisted pharmaceutical research [57].

Building upon these historical foundations, artificial intelligence now offers expanded capabilities in drug synthesis, analysis, and industrial production. Unlike earlier deterministic computational methods, AI systems can learn from large experimental datasets, continuously refine predictive models, and adapt to new information. In synthetic chemistry, machine learning algorithms can propose optimized reaction conditions, predict yields, and anticipate potential side products by recognizing patterns across thousands of prior experiments. In analytical laboratories, AI-driven image and signal processing tools can automate peak detection, impurity profiling, and anomaly identification with enhanced speed and consistency. Within manufacturing environments, real-time data monitoring combined with predictive analytics supports proactive quality control, reduced waste, and improved process stability. Importantly, the integration of AI does not eliminate the need for human expertise; rather, it augments scientific judgment by providing decision-support tools. Effective implementation therefore requires structured human oversight to validate predictions, ensure regulatory compliance, and maintain ethical standards. The objective of this article is to examine systematically where AI can most effectively enhance efficiency in pharmaceutical synthesis, analysis, and production, and where careful human supervision remains essential to safeguard reliability, safety, and scientific integrity.

2. Drug Design / Discovery

2.1. Molecular Modeling & Virtual Screening

Artificial intelligence has significantly transformed molecular modeling and virtual screening in modern drug discovery. Machine learning algorithms and deep neural networks can predict binding affinities between small molecules and biological targets with increasing accuracy, enabling rapid identification of potential lead compounds from vast chemical libraries. By analyzing structural descriptors, physicochemical parameters, and historical bioactivity data, AI systems can prioritize promising candidates before costly laboratory experiments are initiated. This capability substantially reduces the number of experimental trials required, shortens development timelines, and lowers overall research expenditures. Furthermore, AI-driven virtual screening allows exploration of chemical spaces that would be impractical to assess manually, thereby increasing the probability of identifying novel scaffolds. However, these advantages are accompanied by important limitations. Predictive models depend heavily on the quality and diversity of training datasets, and biased or incomplete data may lead to inaccurate predictions or overlooked candidates [58]. Over fitting, limited interpretability of deep learning models, and reduced reliability when extrapolating beyond known chemical space remain critical concerns. Therefore, a human-in-the-loop framework is essential. Expert medicinal chemists must validate computational predictions, assess synthetic feasibility, evaluate toxicity risks, and ensure alignment with therapeutic objectives. In this hybrid approach, AI serves as an acceleration tool, while human expertise safeguards scientific rigor and strategic decision-making.

2.2. Quantitative Structure-Activity Relationship (QSAR) & De Novo Design

Artificial intelligence has markedly enhanced Quantitative Structure–Activity Relationship (QSAR) modeling and de novo drug design by enabling data-driven prediction of chemical activity and automated generation of novel molecular structures. Advanced machine learning algorithms can analyze complex relationships between molecular descriptors and biological responses, constructing predictive models that estimate potency, selectivity, and pharmacokinetic behavior. These models facilitate rapid screening of virtual compounds and significantly accelerate the identification of promising candidates [59]. In parallel, generative AI approaches such as variational autoencoders and generative adversarial networks can propose entirely new molecular entities optimized for predefined biological targets. This capacity to navigate and explore vast

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

regions of chemical space far beyond traditional experimental reach represents a major advantage, reducing reliance on trial-and-error synthesis and expanding opportunities for innovation.

Nevertheless, important challenges remain. QSAR models are inherently dependent on the quality and representativeness of input datasets, and predictive performance may decline when extrapolating beyond known chemical domains. Similarly, AI-generated molecules may appear promising computationally but prove synthetically infeasible, unstable, or biologically unsafe. Therefore, rigorous human oversight is essential. Medicinal chemists and pharmacologists must evaluate AI-generated structures for drug-likeness, toxicity risks, synthetic accessibility, and true novelty. In this collaborative framework, AI enhances exploratory efficiency, while expert judgment ensures scientific validity and therapeutic relevance.

2.3. Target Identification & Biomarker Discovery

Artificial intelligence has become an important tool in target identification and biomarker discovery by enabling the integration and analysis of large-scale genomic, proteomic, and clinical datasets. Modern biomedical research generates complex, high-dimensional data that often exceed the analytical capacity of conventional statistical methods. Machine learning algorithms can uncover hidden patterns, prioritize candidate therapeutic targets linked to disease pathways, and model biological networks to identify key regulatory nodes. In parallel, AI-driven approaches support biomarker discovery by classifying patient subgroups, predicting disease progression, and identifying molecular signatures associated with treatment response. These capabilities strengthen precision medicine strategies and help focus drug development efforts on biologically relevant mechanisms, potentially reducing early-stage attrition rates [60].

However, AI-based discoveries are highly dependent on data quality, representativeness, and appropriate model validation. Statistical associations identified by algorithms may lack mechanistic significance, and biased datasets can compromise generalizability across populations. Therefore, human oversight remains essential to interpret computational outputs critically, confirm biological plausibility, and validate findings experimentally. Expert evaluation ensures that AI-prioritized targets are therapeutically actionable and clinically meaningful [61]. In this collaborative framework, AI accelerates discovery, while human expertise safeguards scientific rigor and translational relevance.

3. Clinical Trials

Artificial intelligence is increasingly influencing the design, execution, and monitoring of clinical trials by enhancing data-driven decision-making and operational efficiency. Machine learning models can analyze historical trial data to optimize protocol design, estimate appropriate sample sizes, and simulate patient responses under varying conditions. AI-assisted patient stratification enables identification of suitable candidates based on genetic, demographic, and clinical characteristics, potentially improving recruitment efficiency and therapeutic response prediction. Additionally, real-time data analytics platforms can monitor adverse events, detect early safety signals, and support adaptive trial designs that modify parameters based on interim results. These capabilities may reduce trial duration, lower operational costs, and increase the probability of successful outcomes [62].

However, clinical research involves complex ethical, regulatory, and safety considerations that cannot be delegated solely to algorithmic systems. AI predictions may be influenced by incomplete datasets, demographic bias, or unrecognized confounding variables. Furthermore, patient safety, informed consent, and compliance with regulatory standards require careful human supervision. Physicians, clinical researchers, and regulatory experts must critically evaluate AI-generated insights before implementing protocol adjustments or making continuation decisions. In this context, AI functions as a decision-support system rather than an autonomous authority. A structured human-in-the-loop framework ensures that efficiency gains do not compromise ethical integrity, scientific validity, or patient safety [63].

4. Drug Synthesis / Manufacturing

4.1. Reaction Optimization & Process Control

Artificial intelligence is increasingly applied to reaction optimization and process control in pharmaceutical manufacturing, where efficiency, reproducibility, and safety are critical. Machine learning models can analyze historical experimental data to predict optimal reaction conditions, including temperature, pressure, solvent systems, catalyst selection, and reagent ratios. By recognizing nonlinear relationships among multiple variables, AI systems can suggest parameter combinations that maximize yield, reduce impurity formation,

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

and minimize energy consumption. In continuous manufacturing environments, real-time process analytical technology (PAT) integrated with AI algorithms enables dynamic monitoring of reaction progress and early detection of deviations. Such predictive control systems can reduce batch failures, improve consistency, and accelerate process development timelines [64].

Despite these advantages, AI-driven optimization must operate within a structured human-in-the-loop framework. Reaction systems in pharmaceutical synthesis often involve complex kinetics, heat transfer limitations, mixing constraints, and safety hazards that may not be fully captured in training datasets. Scale-up from laboratory to pilot or industrial production introduces additional variables such as mass transfer efficiency and equipment-specific behavior. Therefore, experienced process chemists and chemical engineers must validate AI-generated recommendations, assess thermodynamic feasibility, and ensure compliance with safety and regulatory standards. In this integrated model, AI enhances efficiency and predictive capability, while human expertise safeguards robustness, scalability, and operational safety in pharmaceutical manufacturing [65].

4.2. Predictive Maintenance & Equipment Monitoring

Artificial intelligence has emerged as a key tool for predictive maintenance and equipment monitoring in pharmaceutical manufacturing, where uninterrupted operation, reliability, and regulatory compliance are paramount. Machine learning algorithms can continuously analyze sensor data, vibration patterns, temperature fluctuations, and operational parameters to detect early signs of equipment degradation or potential failure. By predicting when pumps, reactors, or filtration systems may malfunction, AI enables proactive maintenance scheduling, reducing unexpected downtime, production losses, and associated costs. Additionally, AI-driven monitoring can optimize equipment utilization, improve energy efficiency, and support adherence to Good Manufacturing Practices (GMP) by flagging deviations from predefined operational norms [66], [67].

Despite these benefits, predictive maintenance systems cannot function autonomously without human oversight. Equipment behavior in pharmaceutical production can be influenced by complex chemical reactions, process variability, and environmental factors that may not be fully captured in historical data. Misinterpretation of AI predictions could lead to unnecessary interventions or overlooked hazards. Therefore, experienced engineers and process chemists must validate alerts, assess criticality, and make final decisions regarding maintenance actions. In this human-in-the-loop framework, AI serves as a continuous monitoring and decision-support tool, providing early warning and data-driven insights, while human expertise ensures operational safety, regulatory compliance, and optimal performance of pharmaceutical manufacturing systems.

4.3. Supply Chain & Inventory Management

Artificial intelligence (AI) is transforming pharmaceutical supply chain and inventory management by introducing unprecedented levels of foresight, efficiency, and resilience. In this complex, globalized industry, timely delivery of raw materials, active pharmaceutical ingredients (APIs), and finished products is paramount, alongside strict adherence to quality and regulatory standards. Machine learning algorithms analyze vast datasets encompassing historical sales, production schedules, supplier performance, geopolitical events, and even real-time weather patterns to predict demand fluctuations, optimize inventory levels, and identify potential disruptions [68]. By forecasting demand with greater accuracy, AI minimizes stockouts and overstocking, thereby reducing waste, storage costs, and the risk of product expiry. Furthermore, AI-driven systems can optimize logistics routes, identify the most reliable suppliers, and proactively flag potential bottlenecks or delays in the supply chain, enhancing overall responsiveness and reducing lead times.

Despite these significant advantages, the intricate nature of pharmaceutical supply chains necessitates vigilant human oversight. AI models, while powerful, may not fully account for unforeseen events such as sudden regulatory changes, novel pathogen outbreaks, or highly localized disruptions that lack historical precedent. Ethical considerations related to drug access and equitable distribution also fall outside the purely algorithmic domain. Therefore, experienced supply chain managers, logistics experts, and regulatory specialists must validate AI-generated forecasts and recommendations, interpret complex market dynamics, and make nuanced decisions, especially during crises or when adapting to new regulations. Within this human-in-the-loop framework, AI acts as a sophisticated analytical and predictive engine, offering early warnings and strategic insights, while human expertise ensures adaptability, ethical decision-making, and robust compliance, ultimately safeguarding the continuous and reliable delivery of essential medicines [69].

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

5. Drug Analysis / Quality Control

5.1. Spectroscopy & Chromatography Analysis

Artificial intelligence has significantly enhanced spectroscopy and chromatography analysis in pharmaceutical research and quality control. Machine learning algorithms can automatically detect peaks, identify impurities, and recognize complex patterns in data generated by high-performance liquid chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance (NMR), and mass spectrometry (MS). By analyzing large datasets rapidly and consistently, AI reduces manual interpretation time, minimizes human error, and improves reproducibility across batches. These capabilities allow laboratories to screen compounds more efficiently, detect subtle variations that may indicate degradation or contamination, and maintain high analytical standards [70], [71].

Despite these advantages, human oversight remains essential. Automated AI predictions may occasionally misidentify peaks or fail to recognize unusual patterns arising from rare impurities, instrumental artifacts, or unexpected chemical behavior. Expert analysts are required to validate AI-generated results, interpret anomalies, and make final decisions regarding sample quality and regulatory compliance. In a human-in-the-loop framework, AI serves as a powerful decision-support tool, accelerating data processing and enhancing consistency, while trained chemists ensure accuracy, contextual understanding, and adherence to stringent quality standards. This integrated approach maximizes analytical efficiency without compromising reliability or safety in pharmaceutical operations.

5.2. Data Analytics & Anomaly Detection

Artificial intelligence plays a key role in pharmaceutical data analytics and anomaly detection, enabling rapid processing of complex datasets from manufacturing, analytical, and clinical operations. Machine learning algorithms can identify patterns, detect deviations, and flag unusual trends that may indicate process drift, contamination, or batch inconsistencies. By continuously monitoring high-dimensional data, AI enhances predictive capabilities, supports quality assurance, and helps prevent costly errors or production delays. However, AI outputs are not infallible. Rare anomalies or context-specific deviations may be misinterpreted if evaluated solely by algorithms. Human oversight is therefore essential to validate flagged events, interpret unexpected patterns, and make informed decisions regarding corrective actions. In a human-in-the-loop framework, AI accelerates detection and decision support, while expert analysts ensure accuracy, reliability, and compliance with regulatory standards, maintaining both operational efficiency and product safety [72], [73].

5.3. Regulatory Compliance Checks

Artificial intelligence is increasingly utilized to support regulatory compliance in pharmaceutical operations by monitoring documentation, tracking process adherence, and ensuring conformity with standard operating procedures (SOPs). Machine learning and natural language processing algorithms can scan vast records, identify missing or inconsistent entries, and flag potential deviations from regulatory standards. By automating routine compliance checks, AI reduces administrative burden, enhances efficiency, and minimizes the risk of oversight in complex documentation workflows [74]. Despite these advantages, human oversight remains critical. Regulatory requirements often involve nuanced interpretation, contextual judgment, and evaluation of exceptions that AI alone cannot reliably address. Expert personnel must review AI-generated alerts, interpret complex guidelines, and determine appropriate corrective actions. In a human-in-the-loop framework, AI functions as a continuous monitoring and support tool, accelerating compliance verification, while regulatory experts ensure accuracy, legal conformity, and adherence to both local and international standards. This integration safeguards both operational efficiency and regulatory integrity in pharmaceutical practice [75].

6. Formulation Development

6.1. Stability Prediction & Excipient Selection

Artificial intelligence has become a valuable tool in formulation development, particularly for predicting drug stability and selecting suitable excipients. Machine learning models can analyze historical stability data, molecular structures, environmental conditions, and excipient interactions to forecast degradation pathways and identify optimal formulation components. By rapidly evaluating numerous excipient combinations and storage conditions, AI accelerates the development of stable and effective pharmaceutical products, reducing

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

trial-and-error experimentation and resource expenditure. Additionally, predictive models can anticipate potential incompatibilities between active pharmaceutical ingredients (APIs) and excipients, guiding rational design and minimizing stability-related risks [76].

Despite these advantages, human oversight is essential to ensure reliability and safety. Chemists and formulation scientists must interpret AI-generated predictions, validate compatibility assessments experimentally, and consider regulatory and patient-specific constraints. Certain chemical interactions or long-term degradation mechanisms may not be fully captured by computational models, requiring expert judgment. In a human-in-the-loop framework, AI serves as a decision-support system, enabling rapid formulation optimization while human experts ensure chemical plausibility, product safety, and compliance with regulatory standards. This synergistic approach maximizes efficiency in formulation development without compromising quality or therapeutic effectiveness [77].

6.2. Release Profile & Dosage Optimization

Artificial intelligence has become an influential tool in optimizing drug release profiles and determining appropriate dosage regimens. Machine learning algorithms can analyze experimental dissolution data, pharmacokinetic and pharmacodynamic parameters, and formulation characteristics to predict how drugs are released and absorbed in the body. By simulating various release mechanisms and dosage scenarios, AI enables rapid identification of optimal formulations that achieve desired therapeutic outcomes, improve bioavailability, and maintain patient safety. These computational approaches reduce the need for extensive trial-and-error testing, accelerating development timelines while maintaining high-quality standards [78].

However, human oversight remains critical. Predicted release profiles may not account for all in vivo factors, patient variability, or complex interactions between drug components and biological systems. Formulation scientists and pharmacologists must validate AI-generated recommendations, interpret model limitations, and adjust dosage and release strategies based on experimental and clinical insights. In a human-in-the-loop framework, AI serves as a powerful tool for predictive modeling and scenario testing, while human experts ensure that final decisions meet safety, efficacy, and regulatory standards. This collaborative approach maximizes efficiency in dosage optimization and release design without compromising therapeutic effectiveness or patient well-being [79].

6.3. Process Scale-Up

Artificial intelligence plays a growing role in process scale-up, bridging laboratory development and industrial production. Machine learning models can predict challenges in scaling reactions, anticipate variations in yield or impurity profiles, and suggest adjustments in equipment or process parameters. By analyzing historical data and pilot-scale experiments, AI helps streamline scale-up planning, reduce trial-and-error, and improve reproducibility. Nevertheless, human oversight remains essential. Process engineers and chemists must validate AI recommendations, consider equipment-specific constraints, and ensure safety and regulatory compliance. In this human-in-the-loop framework, AI accelerates decision-making while expert judgment safeguards feasibility, product quality, and operational efficiency in pharmaceutical manufacturing [80], [81].

7. Interactive Discussion

The integration of artificial intelligence (AI) into pharmaceutical synthesis, analytical characterization, and industrial manufacturing (Table 1) represents a paradigm shift rather than a simple technological upgrade. Unlike conventional empirical methodologies that rely heavily on iterative experimentation and expert intuition, AI-driven systems introduce predictive, adaptive, and data-centric frameworks capable of navigating high-dimensional chemical and process spaces. This shift becomes particularly significant when comparing classical computational approaches such as density functional theory (DFT) with modern machine learning (ML) architectures. While DFT provides mechanistic depth and theoretical rigor, ML models offer scalability, rapid prediction, and real-time adaptability.

However, AI implementation is not without limitations. Predictive accuracy strongly depends on dataset quality, representativeness, and regulatory compliance. In pharmaceutical manufacturing, black-box models may raise validation concerns under Good Manufacturing Practice (GMP) standards. Therefore, the most effective strategy is not replacement of traditional methods but hybrid integration where mechanistic insight, regulatory expertise, and AI-driven prediction operate synergistically.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

Table 1. Comparative Analysis of Traditional vs AI-Driven Pharmaceutical Approaches

Dimension	Traditional Methods	Early Computational Methods (DFT, Docking)	AI / Machine Learning Approaches
Reaction Optimization	Iterative lab trials	Mechanistic energy profiling	Multivariate predictive modeling
Speed	Slow, experimental cycles	Moderate (computationally intensive)	Rapid, scalable predictions
Data Handling	Limited variables	Structured molecular systems	High-dimensional datasets
Mechanistic Insight	Experience-based	Quantum-mechanical depth	Pattern-based inference
Clinical Trial Design	Manual stratification	Statistical modeling	Predictive patient stratification
Analytical Interpretation	Manual peak assignment	Semi-automated tools	Automated pattern recognition
Manufacturing Control	Reactive quality checks	Process simulations	Real-time predictive control
Regulatory Transparency	High interpretability	High theoretical transparency	Requires explainable AI frameworks
Scalability	Limited by lab capacity	Limited by computational cost	Highly scalable with data availability

In analytical chemistry, AI enhances chromatographic peak detection, spectral interpretation, and impurity profiling, reducing manual interpretation bias. In synthesis optimization, machine learning enables multivariate reaction modeling beyond human cognitive limits. Yet human oversight remains essential for mechanistic plausibility assessment and safety validation. Ultimately, AI functions best as a decision-support system rather than an autonomous authority. The future of pharmaceutical innovation lies in structured collaboration between computational intelligence and domain expertise.

Table 2. Comparative Analysis of AI Models in Pharmaceutical Applications and Human Oversight Needs

AI Model Category	Key AI Techniques/Algorithms	Primary Pharmaceutical Applications	Benefits (AI Contribution)	Human Oversight Needs (Key Roles & Rationale)
Machine Learning (ML)	Supervised Learning (e.g., Random Forests, SVMs, Logistic Regression), Unsupervised Learning (e.g., Clustering), Reinforcement Learning	- Drug Discovery: QSAR modeling, ADMET prediction, hit-to-lead optimization. - Clinical Trials: Patient stratification, outcome prediction, adverse event detection. - Manufacturing: Reaction optimization, process control, predictive maintenance. - Formulation: Stability prediction, excipient selection.	- Rapid pattern recognition in structured data. - Predictive modeling from historical data. - Automation of repetitive analytical tasks.	Moderate to High. - Chemists/Biologists: Validate predictions, assess mechanistic plausibility, review data quality, ensure synthetic feasibility. - Clinicians/Statisticians: Interpret patient outcomes, confirm clinical relevance, address bias, ensure ethical compliance - Engineers/Operators: Verify operational feasibility, ensure safety, respond to alerts.
Deep Learning (DL)	Neural Networks (e.g., CNNs, RNNs, Transformers), Generative Models (e.g., GANs, VAEs)	- Drug Discovery: De novo molecular design, protein structure prediction, image analysis (e.g., high-content screening). - Clinical Trials: Biomarker discovery from imaging/omics data, real-time monitoring of complex physiological signals. - Manufacturing: Vision systems for quality inspection, advanced process optimization. - Formulation: Complex multi-parameter optimization.	- Handles high-dimensional, unstructured data (images, sequences). - Generates novel entities (molecules, designs). - Captures complex, non-linear relationships.	High. - Medicinal Chemists/Biophysicists: Assess "drug-likeness" of generated molecules, validate structural predictions, ensure biological relevance. - Data Scientists/AI Ethicists: Address "black-box" interpretability, mitigate bias, ensure model robustness and generalizability. - Experts across domains: Critical validation of complex outputs, safety assessment, regulatory compliance.
Natural Language Processing (NLP)	Text Classification, Information Extraction, Named Entity Recognition, Large Language Models (LLMs)	- Drug Discovery: Literature mining for target identification, pathway analysis, patent analysis. - Clinical Trials: Extracting insights from Electronic Health Records (EHRs), patient diaries, regulatory documents. - Regulatory Affairs: Compliance checking, document generation, summarizing guidelines. - Research: Synthesizing scientific literature, generating hypotheses.	- Automates extraction of insights from vast text data. - Identifies trends and relationships in unstructured information. - Facilitates rapid literature review and compliance tasks.	High. - Domain Experts (e.g., Pharmacologists, Regulatory Specialists, Clinicians): Validate extracted information, verify factual accuracy, ensure contextual understanding, mitigate hallucination risks (for LLMs), ensure privacy and ethical use of patient data. - Legal/Compliance Officers: Review generated documents for legal and regulatory accuracy.

The integration of Artificial Intelligence (AI) into pharmaceutical research and development represents a paradigm shift, fundamentally altering how data is leveraged across various stages. As Table 2 illustrates, different AI model categories containing Machine Learning (ML), Deep Learning (DL), and Natural Language Processing (NLP) offer distinct capabilities and necessitate varying degrees of human oversight. ML

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

techniques, encompassing supervised and unsupervised learning, excel in pattern recognition within structured datasets, proving invaluable for applications like QSAR modeling, ADMET prediction, and optimizing manufacturing processes such as reaction conditions and predictive maintenance. Their strength lies in predictive modeling from historical data and automating repetitive analytical tasks, thereby accelerating initial screening and process control. However, human chemists, biologists, engineers, and clinicians remain crucial for validating predictions, assessing mechanistic plausibility, ensuring data quality, and addressing potential biases, underscoring a moderate to high need for human-in-the-loop supervision [82]-[88].

Deep Learning models, with their advanced neural network architectures, are particularly adept at handling high-dimensional, unstructured data, revolutionizing areas like de novo molecular design, protein structure prediction, and advanced image analysis in drug discovery. Their capacity to generate novel entities and capture complex, non-linear relationships offers unprecedented exploratory power. Yet, the "black-box" nature of many DL models mandates high human oversight. Medicinal chemists, biophysicists, and AI ethicists are essential to assess the "drug-likeness" and biological relevance of generated molecules, mitigate algorithmic bias, and ensure model interpretability and generalizability, especially given the high-stakes nature of drug development.

Finally, NLP techniques, including large language models, significantly enhance information extraction and synthesis from vast textual data, automating literature mining, patent analysis, and compliance checks. This capability streamlines target identification, regulatory documentation, and hypothesis generation. However, the potential for factual inaccuracies, "hallucinations" in LLMs, and the need for contextual understanding necessitate high human involvement. Pharmacologists, regulatory specialists, and clinicians must meticulously validate extracted information, ensure contextual accuracy, and safeguard privacy and ethical data use, confirming that AI acts as a powerful decision-support tool, not an autonomous authority, across the pharmaceutical continuum.

8. Conclusion & Future Directions

Artificial intelligence has demonstrated transformative potential across the entire pharmaceutical lifecycle, from drug discovery and target identification to synthesis, analysis, formulation, and manufacturing. Its capacity to process large-scale, complex datasets, predict outcomes, and optimize multi-parameter processes has significantly accelerated timelines, improved efficiency, and reduced resource consumption. In drug design, AI aids molecular modeling, virtual screening, and de novo molecule generation, while in clinical trials, it enhances patient stratification, protocol optimization, and real-time data monitoring. In manufacturing and quality control, AI supports reaction optimization, predictive maintenance, analytical assessment, and regulatory compliance. Despite these advances, human expertise remains indispensable. AI models are dependent on data quality, may encounter biases, and often require contextual interpretation, especially in high-stakes decisions involving safety, efficacy, and regulatory adherence. A structured human-in-the-loop framework ensures that AI complements, rather than replaces, expert judgment, maintaining scientific rigor, ethical standards, and operational safety. Looking forward, the integration of adaptive AI systems, hybrid computational-human models, and digital twins promises further gains in precision, scalability, and cost-effectiveness. Future research should focus on developing robust, interpretable, and generalizable AI models while fostering close collaboration between AI systems and human experts. Such synergy can fully realize the potential of AI in pharmaceuticals, enhancing productivity, innovation, and patient outcomes without compromising safety or quality.

References

[1] A. Rashi Bhat, S. Ahmed, ‘Artificial Intelligence (AI) in drug design and discovery: A comprehensive review’, Inform. Drug Discovery, vol. 2, pp. 100049, 2025, doi: 10.1016/j.insi.2025.100049.

[2] S. K. Niazi, Artificial intelligence in small-molecule drug discovery: A critical review of methods, applications, and real-world outcomes. Pharmaceuticals, vol. 18, no. 9, pp. 1271, 2025, doi: 10.3390/ph18091271.

[3] N. M. Nagpure, D. Askar, H. Raut, T. Rasala, ‘Artificial Intelligence in Pharmacy–Revolutionising, Discovery, Development and Education’, J. App. Pharma. Sci. Res., vol. 8, no. 4, pp. 1-9, 2025, doi: 10.31069/japsr.v8i4.01

[4] B. Li, K. Tan, A. R. Lao, H. Wang, H. Zheng, L. Zhang, ‘A comprehensive review of artificial intelligence for pharmacology research. Frontiers in Genetics’, vol. 15, pp. 1450529, 2024, doi: 10.3389/fgene.2024.1450529.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

[5] N. M. Aljamali, K. A. A. Alnomani, M. A. Maysaa, 'Review on Computational Biology and Computational Chemistry Applications', Int. J. Cheminform. Res., vol. 7, no. 2, pp. 1-10, 2021, doi: 10.37628/IJCIR.

[6] G. B. Goh, N. O. Hodas, A. Vishnu, 'Deep learning for computational chemistry', J. Comput. Chem., vol. 38, no. 16, pp. 1291-1307, 2017, doi: 10.1002/jcc.24764.

[7] A. Lavecchia, 'Transform drug discovery and development with generative artificial intelligence', Gen. Artif. Intell. Biomed. Smart Health Inform., IEEE, pp. 489-537, 2025, doi: 10.1002/9781394280735.ch25.

[8] H. M. Patel, M. N. Noolvi, P. Sharma, V. Jaiswal, S. Bansal, S. Lohan, V. Bhardwaj, 'Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery', Med. Chem. Res., vol. 23, no. 12, pp. 4991-5007, 2014, doi: 10.1007/s00044-014-1072-3.

[9] S. Priya, G. Tripathi, D. B. Singh, P. Jain, A. Kumar, 'Machine learning approaches and their applications in drug discovery and design', Chem. Biol. Drug Des., vol. 100, no. 1, pp. 136-153, 2022.

[10] J. T. Beck, M. Rammage, G. P. Jackson, A. M. Preininger, I. Dankwa-Mullan, M. C. Roebuck, M. Vinegra, 'Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center', JCO Clin. Cancer Inform., vol. 4, pp. 50-59, 2020, doi:10.1200/CCI.19.00079.

[11] S. A. Siadati, M. A. Ebrahimzadeh, R. Y. Robati, E. Babanezhad, 'How to Manufacture a Drug API? A Simple Scheme from synthesis to analysis', Sci. Rad., vol. 3, no. 2, pp. 89-107, 2024, DOI: 10.58332/scirad2024v3i2a03.

[12] A. Beheshti, Z. Kamalzadeha, M. Haj-Maleka, M. Payaba, M. A. Rezvanfar, S. A. Siadati, 'Development and validation of a reversed-phase HPLC method for determination of assay content of Teriflunomide by the aid of BOMD simulations', Chem. Lett., vol. 10, pp. 281-294, 2021, doi: 10.5267/j.ccl.2021.3.001.

[13] A. Dadras, M. A. Rezvanfar, A. Beheshti, S. S. Naeimi, S. A. Siadati, 'An urgent industrial scheme both for total synthesis, and for pharmaceutical analytical analysis of umifenovir as an anti-viral API for treatment of COVID-19', Comb. Chem. High Throughput Screen., vol. 25, no. 5, pp. 838-846, 2022, doi: 10.2174/1386207324666210203175631.

[14] K. Martinez-Mayorga, A. Madariaga-Mazon, J. L. Medina-Franco, G. Maggiora, 'The impact of chemoinformatics on drug discovery in the pharmaceutical industry', Expert Opin. Drug Discov., vol. 15, no. 3, pp. 293-306, 2020, doi: 10.1080/17460441.2020.1696307.

[15] S. A. Siadati, M. A. Ebrahimzadeh, E. Babanezhad, 'Synthesis routes from Salicylic acid to Mesalazine; A short Review', Tabari Biomed. Stud. Res. J., vol. 7, no. 3, pp. 36-45, 2025.

[16] C. J. Taylor, A. Pomberger, K. C. Felton, R. Grainger, M. Barecka, T. W. Chamberlain, A. A. Lapkin, 'A brief introduction to chemical reaction optimization', Chem. Rev., vol. 123, no. 6, pp. 3089-3126, 2023, doi: 10.1021/acs.chemrev.2c00798.

[17] P. Dastoorani, M. A. Khalilzadeh, F. Khaleghi, M. T. Maghsoodlou, M. R. Zardoost, S. A. Siadati, 'The Diels–Alder Reaction between Euparin and Dimethyl Acetylenedicarboxylate; a Joint Experimental and Density Functional Theory Study', Polycyclic Aromat. Compd., vol. 44, no. 3, pp. 2077-2089, 2024, doi: 10.1080/10406638.2023.2212102.

[18] S. A. Siadati, M. A. Ebrahimzadeh, E. Babanezhad, 'Synthetic Routes from 1-(2-phenylethyl)-4-piperidinone (PPD) to Fentanyl; A Short Review', Tabari Biomed. Stud. Res. J., vol. 7, no. 4, pp. 1-7, 2025.

[19] Z. Hossaini, F. Rostami-Charati, M. Ghambarian, S. A. Siadati, 'Synthesis of a new class of phosphonate derivatives using a three component reaction of trialkyl phosphites or triaryl phosphites in water', Phosphorus Sulfur Silicon Relat. Elem., vol. 190, no. 7, pp. 1177-1182, 2015, doi: 10.1080/10426507.2014.978329.

[20] S. A. Siadati, M. Samadi, M. Soheilizad, L. Firoozpour, M. Payab, S. Bagherpour, B. Dindari, 'A clean industrial scheme for de-ketalization of EIDD-2801 intermediate in water to give molnupiravir (MK-4482) anti-COVID-19 agent (containing its pharmaceutical analytical analysis)', Sci. Rad., vol. 2, pp. 202-216, 2022, doi: 10.58332/scirad2023v2i2a05.

[21] C. S. Latchubugata, R. V. Kondapaneni, K. K. Patluri, U. Virendra, S. Vedantam, 'Kinetics and optimization studies using Response Surface Methodology in biodiesel production using heterogeneous catalyst', Chem. Eng. Res. Des., vol. 135, pp. 129-139, 2018, doi: 10.1016/J.CHERD.2018.05.022.

[22] S. A. Siadati, M. Soheilizad, L. Firoozpour, M. Samadi, M. Payab, S. Bagherpour, S. M. Mousavi, 'An Industrial Approach to Production of Tofacitinib Citrate (TFC) as an Anti-COVID-19 Agent: A Joint

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

Experimental and Theoretical Study', J. Chem., vol. 2022, no. 1, art. 8759235, 2022, doi: 10.1155/2022/8759235.

[23] R. Jasiński, 'A reexamination of the molecular mechanism of the Diels–Alder reaction between tetrafluoroethene and cyclopentadiene', React. Kinet. Mech. Catal., vol. 119, no. 1, pp. 49-57, 2016, doi: 10.1007/s11144-016-1038-1.

[24] S. A. Siadati, 'A theoretical study on stepwise-And concertedness of the mechanism of 1, 3-Dipolar cycloaddition reaction between tetra amino ethylene and trifluoro methyl azide', Comb. Chem. High Throughput Screen., vol. 19, no. 2, pp. 170-175, 2016, doi: 10.2174/1386207319666151216145408.

[25] Q. Ma, S. Mu, 'Acidic oxygen evolution reaction: Mechanism, catalyst classification, and enhancement strategies', Interdiscip. Mater., vol. 2, no. 1, pp. 53-90, 2023, doi: 10.1002/idm2.12059.

[26] S. A. Siadati, 'Effect of steric congestion on the stepwise character and synchronicity of a 1, 3-dipolar reaction of a nitrile ylide and an olefin', J. Chem. Res., vol. 39, no. 11, pp. 640-644, 2015, doi: 10.3184/174751915X14448371200600.

[27] F. Kareem, Q. Qadeer, I. M. Idriss, Z. Hashmi, S. Sumaiya, 'Scale-up constraint from lab scale to industrial scale', Biotechnol. Eng., pp. 375-388, Elsevier, 2025, doi: 10.1016/B978-0-443-31476-6.00021-X.

[28] S. D. Zondag, D. Mazzarella, T. Noël,' Scale-up of photochemical reactions: transitioning from lab scale to industrial production', Annu. Rev. Chem. Biomol. Eng., vol. 14, pp. 283-300, 2023, doi: 10.1146/annurev-chembioeng-101121-074313.

[29] S. A. Siadati, M. A. Rezvanfar, M. Payab, A. Beheshti, 'Development and validation of a short runtime method for separation of trace amounts of 4-aminophenol, phenol, 3-nitrosalicylic acid and mesalamine by using HPLC system', Chem. Lett., vol. 10, pp. 151-160, 2021, doi: 10.5267/j.ccl.2020.12.002.

[30] S. A. Siadati, M. Payab, A. Beheshti, 'Development of a reversed-phase HPLC method for determination of related impurities of Lenalidomide', Chem. Rev. Lett., vol. 3, no. 2, pp. 61-64, 2020, doi: 10.22034/crl.2020.224059.1042.

[31] R. Schiewek, M. Lorenz, R. Giese, K. Brockmann, T. Benter, S. Gäb, O. J. Schmitz, 'Development of a multipurpose ion source for LC-MS and GC-API MS', Anal. Bioanal. Chem., vol. 392, no. 1, pp. 87-96, 2008, doi: 10.1007/s00216-008-2255-x.

[32] A. Beheshti, M. Payab, V. Seyyed-Ali-Karbasi, S. A. Siadati, 'An unexpected aerobic oxidation of α-amino boronic acid part of Borteomib, leading to (thermal) decomposition of this very expensive anti-cancer API', Curr. Chem. Lett., vol. 11, pp. 227-236, 2022, doi: 10.5267/j.ccl.2021.12.001.

[33] L. S. Almeida, J. Carneiro, L. A. Colnago, 'Time domain NMR for polymorphism characterization: Current status and future perspectives', Int. J. Pharm., vol. 669, art. 125027, 2025, doi: 10.1016/j.ijpharm.2024.125027.

[34] F. Rostami-Charati, Z. Hossaini, F. Sheikholeslami-Farahani, Z. Azizi, S. Amir Siadati, 'Synthesis of 9H-furo [2, 3-f] chromene derivatives by promoting ZnO nanoparticles', Comb. Chem. High Throughput Screen., vol. 18, no. 9, pp. 872-880, 2015, doi: 10.2174/1386207318666150525094109.

[35] F. Meissner, J. Geddes-McAlister, M. Mann, M. Bantscheff, 'The emerging role of mass spectrometry-based proteomics in drug discovery', Nat. Rev. Drug Discov., vol. 21, no. 9, pp. 637-654, 2022, doi: 10.1038/s41573-022-00409-3.

[36] C. Suarez-Oubina, P. Cabarcos-Fernández, M. J. Tabernero-Duque, P. Bermejo-Barrera, A. Moreda-Pineiro, A. M. Bermejo-Barrera, 'Synthetic cathinones determination by liquid chromatography-mass spectrometry after ultrasound membrane assisted extraction', Microchem. J., vol. 191, art. 108869, 2023, doi: 10.1016/j.microc.2023.108869.

[37] L. L. Ng, K. Huynh-Ba (Ed.), 'Development and validation of analytical procedures', Anal. Test. Pharm. GMP Lab., pp. 143-167, 2022, doi:.1002/9781119680475.ch5.

[38] A. M. Bran, S. Cox, O. Schilter, C. Baldassari, A. D. White, P. Schwaller, 'ChemCrow: Augmenting large-language models with chemistry tools', arXiv preprint arXiv:2304.05376, 2023, doi: 10.48550/arXiv.2304.05376

[39] A. A. Aldubayyan, E. Castrignanò, S. Elliott, V. Abbate, 'A quantitative LC–MS/MS method for the detection of 16 synthetic cathinones and 10 metabolites and its application to suspicious clinical and forensic urine samples', Pharmaceuticals, vol. 15, no. 5, art. 510, 2022, doi: 10.3390/ph15050510.

[40] T. E. Ata, I. Al-Ani, N. Karameh, M. R. Atta, W. A. Dayyih, 'Alectinib-loaded chitosan–alginate nanoparticles: a novel synthesis method with in vitro and in vivo evaluations', Pharmaceutics, vol. 17, no. 4, art. 492, 2025, doi: 10.3390/pharmaceutics17040492.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

[41] M. Gashaw, T. Layloff, A. Hymete, A. Ashenef, 'Stability indicating high performance thin layer chromatography method development and validation for quantitative determination of tetracycline hydrochloride in tetracycline hydrochloride active pharmaceutical ingredient (API) and its dosage forms', BMC Chem., vol. 18, no. 1, art. 82, 2024, doi: 10.1186/s13065-024-01183-6.

[42] P. Gowda, A. N. Gowda, 'Best Practices in REST API Design for Enhanced Scalability and Security', J. Artif. Intell. Mach. Learn. Data Sci., vol. 2, no. 1, pp. 827-830, 2024, doi: 10.51219/JAIMLD/priyanka-gowda/202.

[43] G. Kotte, 'Overcoming Challenges and Driving Innovations in API Design for High-Performance Ai Applications', J. Adv. Future Res., vol. 3, no. 4, pp. 125-129, 2025, doi: 10.56975/jaafr.v3i4.500282.

[44] A. R. Bekhradnia, S. Arshadi, S. A. Siadati, '1, 3-Dipolar cycloaddition between substituted phenyl azide and 2, 3-dihydrofuran', Chem. Pap., vol. 68, no. 2, pp. 283-290, 2014, doi: 10.2478/s11696-013-0440-7.

[45] S. A. Siadati, S. Davoudi, M. Soheilizad, L. Firoozpour, M. Payab, S. Bagherpour, S. Kolivand, 'The synthesis and the mechanism of a five-membered ring formation between an isothiocyanate and an amide leading to the yield of Enzalutamide anticancer API; a joint experimental and theoretical study', J. Mol. Struct., vol. 1280, art. 135057, 2023, doi: 10.1016/j.molstruc.2023.135057.

[46] M. Ruggenthaler, D. Sidler, A. Rubio, 'Understanding polaritonic chemistry from ab initio quantum electrodynamics', Chem. Rev., vol. 123, no. 19, pp. 11191-11229, 2023, doi: 10.1021/acs.chemrev.2c00788.

[47] B. Mohtat, S. A. Siadati, M. A. Khalilzadeh, 'Understanding the mechanism of the 1, 3-dipolar cycloaddition reaction between a thioformaldehyde S-oxide and cyclobutadiene: Competition between the stepwise and concerted routes', Prog. React. Kinet. Mech., vol. 44, no. 3, pp. 213-221, 2019, doi: 10.1177/14686783198458.

[48] S. A. Siadati, M. A. Ebrahimzadeh, R. Yazdian-Robati, E. Babanezhad, 'A theoretical approach on the possibility of using α-phographene, g-X3N4 nanosheets, and C19X fullerenes for adsorption and drug delivery of a proteasome inhibitor drug', Diamond Relat. Mater., vol. 147, art. 111344, 2024, doi: 10.1016/j.diamond.2024.111344.

[49] B. Mohtat, S. A. Siadati, M. A. Khalilzadeh, D. Zareyee, 'The concern of emergence of multi-station reaction pathways that might make stepwise the mechanism of the 1, 3-dipolar cycloadditions of azides and alkynes', J. Mol. Struct., vol. 1155, pp. 58-64, 2018, doi: 10.1016/j.molstruc.2017.10.034.

[50] S. A. Siadati, M. Alinezhad, 'A theoretical study on the functionalisation process of C18NB fullerene through its open [5, 5] cycloaddition with 4-pyridine nitrile oxide', Prog. React. Kinet. Mech., vol. 40, no. 2, pp. 169-176, 2015, doi: 10.3184/146867815X142626120084.

[51] M. H. Shaikh, S. P. Kunde, V. M. Khedkar, D. N. Pansare, A. P. Sarkate, S. R. Thopate, 'Computer-Aided Drug Synthesis and Design', Artif. Intell. Chem. Sci., pp. 19-56, 2025.

[52] M. A. H. Ismail, D. A. Abou El Ella, K. A. M. Abouzid, G. H. A. Al-Ansary, 'Computer-based drug design, synthesis and biological evaluation of new pyrimidinone derivatives linked to arylpiperazine and 2'-carbethoxy-biphenylylmethyl moeities as α1-adrenoceptor antagonists and angiotensin II AT1 receptor antagonists', Die Pharmazie-An Int. J. Pharm. Sci., vol. 65, no. 11, pp. 794-800, 2010.

[53] S. A. Siadati, 'Beyond the alternatives that switch the mechanism of the 1, 3-dipolar cycloadditions from concerted to stepwise or vice versa: a literature review', Prog. React. Kinet. Mech., vol. 41, no. 4, pp. 331-344, 2016, doi: 10.3184/146867816X14719552202.

[54] S. A. Siadati, 'The Effect of Position Replacement of Functional Groups on the Stepwise character of 1, 3-Dipolar Reaction of a Nitrile Oxide and an Alkene', Helv. Chim. Acta, vol. 99, no. 4, pp. 273-280, 2016, doi: 10.1002/hlca.201500165.

[55] P. A. Vargas-Rosales, A. Caflisch, 'The physics-AI dialogue in drug design', RSC Med. Chem., vol. 16, no. 4, pp. 1499-1515, 2025, doi: 10.1039/D4MD00869C.

[56] C. Hasselgren, T. I. Oprea, 'Artificial intelligence for drug discovery: are we there yet?', Annu. Rev. Pharmacol. Toxicol., vol. 64, no. 1, pp. 527-550, 2024, doi: 10.1146/annurev-pharmtox-040323-040828.

[57] L. Yang, Q. Guo, L. Zhang, 'AI-assisted chemistry research: a comprehensive analysis of evolutionary paths and hotspots through knowledge graphs', Chem. Commun., vol. 60, no. 55, pp. 6977-6987, 2024, doi: 10.1039/D4CC01892C.

[58] T. A. D. Oliveira, M. P. D. Silva, E. H. B. Maia, A. M. D. Silva, A. G. Taranto, 'Virtual screening algorithms in drug discovery: a review focused on machine and deep learning methods', Drugs Drug Candidates, vol. 2, no. 2, pp. 311-334, 2023, doi: 10.3390/ddc2020017.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

[59] M. Koirala, L. Yan, Z. Mohamed, M. DiPaola, 'AI Integrated QSAR Modeling for Enhanced Drug Discovery: From Classical Approaches to Deep Learning and Structural Insight', Int. J. Mol. Sci., vol. 26, no. 19, art. 9384, 2025, doi: 10.3390/ijms26199384.

[60] E. U. Alum, 'AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis', Discov. Oncol., vol. 16, no. 1, art. 313, 2025, doi: 10.1007/s12672-025-02064-7.

[61] F. J. N. Ferreira, A. S. Carneiro, 'AI driven drug discovery: A comprehensive review', ACS Omega, vol. 10, no. 23, pp. 23889–23903, 2025, doi: 10.1021/acsomega.5c00549.

[62] D. B. Olawade, S. C. Fidelis, S. Marinze, E. Egbon, A. Osunmakinde, A. Osborne, 'Artificial intelligence in clinical trials: A comprehensive review of opportunities, challenges, and future directions', Int. J. Med. Inform., vol. 206, art. 106141, 2025, doi: 10.1016/j.ijmedinf.2025.106141.

[63] D. Teodoro, N. Naderi, A. Yazdani, B. Zhang, A. Bornet, 'A scoping review of artificial intelligence applications in clinical trial risk assessment', NPJI Digit. Med., vol. 8, no. 1, art. 486, 2025, doi: 10.1038/s41746-025-01886-7.

[64] C. He, C. Zhang, T. Bian, K. Jiao, W. Su, K. J. Wu, A. Su, 'A review on artificial intelligence enabled design, synthesis, and process optimization of chemical products for industry 4.0', Processes, vol. 11, no. 2, art. 330, 2023, doi: 10.3390/pr11020330.

[65] D. J. Griffin, C. W. Coley, S. A. Frank, J. M. Hawkins, K. F. Jensen, 'Opportunities for machine learning and artificial intelligence to advance synthetic drug substance process development', Org. Process Res. Dev., vol. 27, no. 11, pp. 1868-1879, 2023, doi: 10.1021/acs.oprd.3c00229.

[66] J. P. S. Saini, A. Thakur, D. Yadav, 'AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations', RSC Pharmaceutics, vol. 2, no. 3, pp. 437-454, 2025, doi: 10.1039/D4PM00323C.

[67] R. Kodumuru, S. Sarkar, V. Parepally, J. Chandarana, 'Artificial intelligence and internet of things integration in pharmaceutical manufacturing: a smart synergy', Pharmaceutics, vol. 17, no. 3, art. 290, 2025, doi: 10.3390/pharmaceutics17030290.

[68] S. Nuta, A. S. Mattam, N. R. Marri, S. Polenwar, 'Artificial Intelligence in Pharmaceutical Supply Chain Management', IJSAT-Int. J. Sci. Technol., vol. 16, no. 3, 2025.

[69] A. Kathiriya, 'A Review of RFID Technology's Impact on Inventory Management and Supply Chain Optimization', Int. J. Emerg. Res. Eng. Technol., vol. 6, no. 3, pp. 86-94, 2025, doi: 10.63282/3050-922X.IJERET-V6I3P110.

[70] N. C. Spies, C. W. Farnsworth, R. Jackups Jr, 'Data-driven anomaly detection in laboratory medicine: past, present, and future', J. Appl. Lab. Med., vol. 8, no. 1, pp. 162-179, 2023, doi: 10.1093/jalm/jfac114.

[71] K. Zai, A. P. Mukti, G. S. Notty, S. U. Niswah, F. Oktivendra, 'Artificial intelligence in the non-clinical laboratory: enhancing good laboratory and documentation practices', Int. J. Pharm., art. 126266, 2025, doi: 10.1016/j.ijpharm.2025.126266.

[72] G. C. Saha, L. N. Eni, H. Saha, P. K. Parida, R. Rathinavelu, S. K. Jain, B. Haldar, 'Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making', Riv. Ital. Filos. Anal. Junior, vol. 14, no. 2, 2023.

[73] V. Rousopoulou, T. Vafeiadis, A. Nizamis, I. Iakovidis, L. Samaras, A. Kirtsoglou, D. Tzovaras, 'Cognitive analytics platform with AI solutions for anomaly detection', Comput. Ind., vol. 134, art. 103555, 2022, doi: 10.1016/j.compind.2021.103555.

[74] R. S. Patil, S. B. Kulkarni, V. L. Gaikwad, 'Artificial intelligence in pharmaceutical regulatory affairs', Drug Discov. Today, vol. 28, no. 9, art. 103700, 2023, doi: 10.1016/j.drudis.2023.103700.

[75] S. Nair, 'Explainable AI in GXP validation: Balancing automation, traceability, and regulatory trust in the pharmaceutical industry', Clin. Med. Health Res. J., vol. 5, no. 05, pp. 1430-1442, 2025, doi: 10.18535/cmhrj.v5i05.509.

[76] A. Dangeti, D. G. Bynagari, K. Vydani, 'Revolutionizing drug formulation: Harnessing artificial intelligence and machine learning for enhanced stability, formulation optimization, and accelerated development', Int. J. Pharm. Sci. Med., vol. 8, no. 8, pp. 18-29, 2023, doi: 10.47760/ijpsm.2023.v08i08.003.

[77] E. Adamec, Y. Babayan, B. Catacchio, A. Coon, A. Dill, M. Fu, C. Wannere, 'Lean stability case studies—leveraging science-and risk-based approaches to enable meaningful phase specific pharmaceutical stability strategies', J. Pharm. Innov., vol. 16, no. 3, pp. 566-574, 2021, doi: 10.1007/s12247-020-09463-z.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03

[78] N. R. Mitta, 'AI-Powered Drug Formulation Optimization: Leveraging Machine Learning for Predictive Modeling of Formulation Stability, Release Profiles, and Manufacturing Processes', Artif. Intell., Mach. Learn., Auton. Syst., vol. 8, pp. 98-134, 2024.

[79] L. K. Vora, A. D. Gholap, K. Jetha, R. R. S. Thakur, H. K. Solanki, V. P. Chavda, 'Artificial intelligence in pharmaceutical technology and drug delivery design', Pharmaceutics, vol. 15, no. 7, art. 1916, 2023, doi: 10.3390/pharmaceutics15071916.

[80] M. Landin, 'Artificial intelligence tools for scaling up of high shear wet granulation process', J. Pharm. Sci., vol. 106, no. 1, pp. 273-277, 2017, doi: 10.1016/j.xphs.2016.09.022.

[81] J. Joseph, 'AI-Driven Synthetic Biology and Drug Manufacturing Optimization', Int. J. Innov. Res. Comput. Commun. Eng., vol. 12, no. 1138, pp. 10-15680, 2024.

[82] J. He, Ch. Hua, Y. Wang, Z. Zheng, 'Collaborative intelligence in sequential experiments: A human-in-the-loop framework for drug discovery', Inform. Sys. Res., pp. 1-26, 2025, doi: 10.1287/isre.2024.1154.

[83] D.B. Olawade, S.B. Plabon, A. Ojo, M.A. Ogunbona, B.D. Makanjuola, R. Olasilola, 'Human in the loop artificial intelligence in healthcare: applications, outcomes, and implementation challenges', Int. J. Med. Inform., vol. 213, pp.106362, 2026, doi: 10.1016/j.ijmedinf.2026.106362.

[84] S. Bakken, 'AI in health: keeping the human in the loop', J. Am. Med. Inform. Assoc., vol. 30, no. 7, pp. 1225-1226, 2023, doi: 10.1093/jamia/ocad091.

[85] A. Gadiko, 'The Role of Human-in-the-Loop in AI Driven Clinical Trials', IJRES, vol. 12, no. 4, pp. 293-299, 2024.

[86] A. U. Rehman, W. Li, B. Wu, Y. Ali, S. Rasheed, S. Shaheen, X. Liu, R. Luo, J. Zhang, 'Role of artificial intelligence in revolutionizing drug discovery', Fundam. Res., vol. 5, no. 3, pp.1273-1287, 2025, doi: 10.1016/j.fmre.2024.04.021.

[87] I. Sundin, A. Voronov, H. Xiao, K. Papadopoulos, E.J. Bjerrum, M. Heinonen, A. Patronov, S. Kaski, O. Engkvist, 'Human-in-the-loop assisted de novo molecular design'. J. Cheminform., vol. 14, no. 1, pp. 86, 2022, doi: 10.1186/s13321-022-00667-8.

[88] A. Kanakia, M. Sale, L. Zhao, Z. Zhou, 'AI in action: redefining drug discovery and development', J. Clin. Transl. Res., vol. 18, no. 2, pp. e70149, 2025, doi: 10.1111/cts.70149.

ISSN: 2956-4808
DOI: 10.58332/scirad2026v5i2a03